Topics

BMS Gets US Approval Of Ozanimod For Relapsing MS, But Launch Delayed

14:18 EDT 26 Mar 2020 | SCRIP

Zeposia, one of three Celgene candidates central to last year’s merger with BMS, obtains US FDA approval in relapsing MS...

      

Related Stories

 

Original Article: BMS Gets US Approval Of Ozanimod For Relapsing MS, But Launch Delayed

NEXT ARTICLE

More From BioPortfolio on "BMS Gets US Approval Of Ozanimod For Relapsing MS, But Launch Delayed"

Quick Search

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...